carbamates has been researched along with Multiple Sclerosis in 8 studies
Multiple Sclerosis: An autoimmune disorder mainly affecting young adults and characterized by destruction of myelin in the central nervous system. Pathologic findings include multiple sharply demarcated areas of demyelination throughout the white matter of the central nervous system. Clinical manifestations include visual loss, extra-ocular movement disorders, paresthesias, loss of sensation, weakness, dysarthria, spasticity, ataxia, and bladder dysfunction. The usual pattern is one of recurrent attacks followed by partial recovery (see MULTIPLE SCLEROSIS, RELAPSING-REMITTING), but acute fulminating and chronic progressive forms (see MULTIPLE SCLEROSIS, CHRONIC PROGRESSIVE) also occur. (Adams et al., Principles of Neurology, 6th ed, p903)
| Excerpt | Relevance | Reference |
|---|---|---|
| " Here, we show that oral dosing with SNJ-1945, a novel water-soluble calpain inhibitor, reduces experimental autoimmune encephalomyelitis clinical scores in vivo and has a two pronged effect via anti-inflammation and protection against neurodegeneration." | 5.40 | Effects of a novel orally administered calpain inhibitor SNJ-1945 on immunomodulation and neurodegeneration in a murine model of multiple sclerosis. ( Azuma, M; Banik, NL; Beeson, C; Haque, A; Inoue, J; Smith, A; Trager, N; Wallace Iv, G, 2014) |
| "In recent years several new treatments have been introduced in neurology, sumatriptan in migraine, riluzole in amyotrophic lateral sclerosis, interferon-beta in multiple sclerosis and rivastigmine in Alzheimer's disease." | 4.80 | [New therapies in neurology, but who benefits?]. ( de Haan, RJ; Vermeulen, M, 1999) |
| " Here, we show that oral dosing with SNJ-1945, a novel water-soluble calpain inhibitor, reduces experimental autoimmune encephalomyelitis clinical scores in vivo and has a two pronged effect via anti-inflammation and protection against neurodegeneration." | 1.40 | Effects of a novel orally administered calpain inhibitor SNJ-1945 on immunomodulation and neurodegeneration in a murine model of multiple sclerosis. ( Azuma, M; Banik, NL; Beeson, C; Haque, A; Inoue, J; Smith, A; Trager, N; Wallace Iv, G, 2014) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 1 (12.50) | 18.7374 |
| 1990's | 1 (12.50) | 18.2507 |
| 2000's | 1 (12.50) | 29.6817 |
| 2010's | 5 (62.50) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Trager, N | 1 |
| Smith, A | 1 |
| Wallace Iv, G | 1 |
| Azuma, M | 2 |
| Inoue, J | 2 |
| Beeson, C | 1 |
| Haque, A | 1 |
| Banik, NL | 2 |
| Rosenberger, TA | 1 |
| Bernal-Chico, A | 1 |
| Canedo, M | 1 |
| Manterola, A | 1 |
| Victoria Sánchez-Gómez, M | 1 |
| Pérez-Samartín, A | 1 |
| Rodríguez-Puertas, R | 1 |
| Matute, C | 1 |
| Mato, S | 1 |
| Podbielska, M | 1 |
| Das, A | 1 |
| Smith, AW | 1 |
| Chauhan, A | 1 |
| Ray, SK | 1 |
| Nozaki, K | 1 |
| Hogan, EL | 1 |
| Chabwine, JN | 1 |
| Rossetti, AR | 1 |
| Hirt, L | 1 |
| Kuntzer, T | 1 |
| Schluep, M | 1 |
| Michel, P | 1 |
| Démonet, JF | 1 |
| du Pasquier, RA | 1 |
| Vingerhoets, FG | 1 |
| Parry, AM | 1 |
| Scott, RB | 1 |
| Palace, J | 1 |
| Smith, S | 1 |
| Matthews, PM | 1 |
| THIEMEYER, JS | 1 |
| Vermeulen, M | 1 |
| de Haan, RJ | 1 |
1 review available for carbamates and Multiple Sclerosis
| Article | Year |
|---|---|
[New therapies in neurology, but who benefits?].
Topics: Alzheimer Disease; Amyotrophic Lateral Sclerosis; Antiviral Agents; Carbamates; Humans; Interferon-b | 1999 |
1 trial available for carbamates and Multiple Sclerosis
| Article | Year |
|---|---|
Potentially adaptive functional changes in cognitive processing for patients with multiple sclerosis and their acute modulation by rivastigmine.
Topics: Adult; Carbamates; Cholinesterase Inhibitors; Cognition; Double-Blind Method; Female; Humans; Image | 2003 |
6 other studies available for carbamates and Multiple Sclerosis
| Article | Year |
|---|---|
Effects of a novel orally administered calpain inhibitor SNJ-1945 on immunomodulation and neurodegeneration in a murine model of multiple sclerosis.
Topics: Animals; Blotting, Western; Calpain; Carbamates; Cell Proliferation; Cell Separation; Cysteine Prote | 2014 |
Targeting calpain-mediated proteolysis and peptide signaling as a strategy to reduce injury in multiple sclerosis.
Topics: Animals; Calpain; Carbamates; Cysteine Proteinase Inhibitors; Encephalomyelitis, Autoimmune, Experim | 2014 |
Blockade of monoacylglycerol lipase inhibits oligodendrocyte excitotoxicity and prevents demyelination in vivo.
Topics: Amidohydrolases; Animals; Benzamides; Benzodioxoles; Cannabinoid Receptor Modulators; Carbamates; De | 2015 |
Neuron-microglia interaction induced bi-directional cytotoxicity associated with calpain activation.
Topics: Animals; Calpain; Carbamates; Cell Survival; Cysteine Proteinase Inhibitors; Dipeptides; Enzyme Acti | 2016 |
[Neurology].
Topics: Antibodies, Monoclonal; Anticonvulsants; Atrial Fibrillation; Carbamates; Chronic Disease; Deep Brai | 2012 |
Mephenesin carbamate in the treatment of multiple sclerosis.
Topics: Carbamates; Humans; Mephenesin; Multiple Sclerosis; Psychotherapy, Multiple | 1959 |